<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhao Y</submitter><funding>NIDDK NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>2747</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9117670</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>Cation-chloride cotransporters (CCCs) NKCC1 and NKCC2 catalyze electroneutral symport of 1 Na&lt;sup>+&lt;/sup>, 1 K&lt;sup>+&lt;/sup>, and 2 Cl&lt;sup>-&lt;/sup> across cell membranes. NKCC1 mediates trans-epithelial Cl&lt;sup>-&lt;/sup> secretion and regulates excitability of some neurons and NKCC2 is critical to renal salt reabsorption. Both transporters are inhibited by the so-called loop diuretics including bumetanide, and these drugs are a mainstay for treating edema and hypertension. Here, our single-particle electron cryo-microscopy structures supported by functional studies reveal an outward-facing conformation of NKCC1, showing bumetanide wedged into a pocket in the extracellular ion translocation pathway. Based on these and the previously published inward-facing structures, we define the translocation pathway and the conformational changes necessary for ion translocation. We also identify an NKCC1 dimer with separated transmembrane domains and extensive transmembrane and C-terminal domain interactions. We further define an N-terminal phosphoregulatory domain that interacts with the C-terminal domain, suggesting a mechanism whereby (de)phosphorylation regulates NKCC1 by tuning the strength of this domain association.</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide.</pubmed_title><pmcid>PMC9117670</pmcid><funding_grant_id>U24 GM129547</funding_grant_id><funding_grant_id>U24 GM129539</funding_grant_id><funding_grant_id>R01 DK128592</funding_grant_id><pubmed_authors>Roy K</pubmed_authors><pubmed_authors>Vidossich P</pubmed_authors><pubmed_authors>Cancedda L</pubmed_authors><pubmed_authors>De Vivo M</pubmed_authors><pubmed_authors>Forbush B</pubmed_authors><pubmed_authors>Cao E</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide.</name><description>Cation-chloride cotransporters (CCCs) NKCC1 and NKCC2 catalyze electroneutral symport of 1 Na&lt;sup>+&lt;/sup>, 1 K&lt;sup>+&lt;/sup>, and 2 Cl&lt;sup>-&lt;/sup> across cell membranes. NKCC1 mediates trans-epithelial Cl&lt;sup>-&lt;/sup> secretion and regulates excitability of some neurons and NKCC2 is critical to renal salt reabsorption. Both transporters are inhibited by the so-called loop diuretics including bumetanide, and these drugs are a mainstay for treating edema and hypertension. Here, our single-particle electron cryo-microscopy structures supported by functional studies reveal an outward-facing conformation of NKCC1, showing bumetanide wedged into a pocket in the extracellular ion translocation pathway. Based on these and the previously published inward-facing structures, we define the translocation pathway and the conformational changes necessary for ion translocation. We also identify an NKCC1 dimer with separated transmembrane domains and extensive transmembrane and C-terminal domain interactions. We further define an N-terminal phosphoregulatory domain that interacts with the C-terminal domain, suggesting a mechanism whereby (de)phosphorylation regulates NKCC1 by tuning the strength of this domain association.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2024-11-10T08:44:24.157Z</modification><creation>2024-11-10T08:44:24.157Z</creation></dates><accession>S-EPMC9117670</accession><cross_references><pubmed>35585053</pubmed><doi>10.1038/s41467-022-30407-3</doi></cross_references></HashMap>